FDA approves new aerosol delivery system for use

Monday, October 31, 2005

MURRYSVILLE, Pa. - The FDA has cleared the Respironics I-neb Adaptive Aerosol Delivery (AAD) System for use by patients. The AAD technology continually monitors and adapts to the individual patient's breathing to deliver a precise dose of medication during inhalation. By the end of this year, CoTherix, a San Francisco-based biopharmaceutical, will use the I-neb device to deliver its Ventavis Inhalation Solution to treat pulmonary arterial hypertension.